Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos.
Popular Articles

Pelosi Statement On Energy And Commerce Committee Passage Of Health Insurance Reform Legislation
Speaker Nancy Pelosi issued the following statement tonight on the vote by the House Energy and Commerce Committee to pass the America"s Affordable Health Choices Act, the third House committee to pass the bill this month. The House Ways and Means Committee and Education and Labor Committee approved the bill earlier this month:
pharmacy online
Genetic Testing May Be Valuable In Treating Colorectal Cancer
For the 29,000 patients in the United States with metastatic colorectal cancer, chemotherapy with irinotecan is a standard treatment that has been shown to improve survival. But for more than one in 10 of these patients, a variation in their DNA means that this treatment could result in a severe reduction in their white blood cell count, leading to a high risk of bacterial infection and possible subsequent death. A new genetic test can identify those with the variation in order to lower the treatment dose - however, it has been unclear whether the testing is worthwhile.
News of the day
Macular Degeneration: The 'See Food' Diet
Current research suggests that a diet high in omega-3 fatty acids may help prevent one of the leading causes of legal blindness among the elderly. The related report by Tuo et al, "A high omega-3 fatty acid diet reduces retinal lesions in a murine model of macular degeneration," appears in the August 2009 issue of the American Journal of Pathology.
Sexual Health

Clinical And Cost Benefits To Promote Uptake Of Advanced Wound Management Technologies Across Europe

The advanced wound management market in Europe is experiencing high growth due to the heightened need for better and more cost-effective treatment. As a result, the market is expanding strongly despite significant hurdles, including intense competition and low reimbursement. New analysis from Frost & Sullivan , Western European Advanced Wound Management Market, finds that the market earned revenues of $1.52 billion in 2008 and estimates this to reach $4.35 billion in 2015. The following segments are covered in the research: moist wound dressings segment, antimicrobial wound dressings segment, NPWT segment and advanced therapies segment. "Rising awareness about chronic wound care in hospitals and home care is supporting the expansion of the advanced wound care market in Europe," notes Frost & Sullivan Research Associate Sreevidhya Praveen. "The market is gaining in popularity against a backdrop of efforts to reduce healthcare expenditure." Advanced wound care products enable speedy recovery from wounds. Therefore, they help curtail healthcare expenditure. Due to the clinical and cost benefits that they offer, demand for such advanced wound management products is increasing. The rising incidence of chronic wounds due to an expanding diabetic population, together with an ageing population across Western Europe is also fuelling the uptake of advanced wound care devices. Changing healthcare systems across Europe are promoting the growth of the advanced wound care products market; physicians are mostly advised to prescribe treatments that would help patients make a speedy recovery and encourage faster healing of wounds. "Currently, the challenge to be overcome in the market is product pricing," cautions Praveen. "Generally, advanced wound care products are more expensive than traditional equivalents." As advanced wound care products are more expensive, reimbursement does not cover these products completely. This, in turn, restrains market growth to a certain extent. Improving wound care education and training for patients and physicians is critical. This will enhance awareness levels about advanced wound care products and their beneficial effect on chronic wound healing. Western European Advanced Wound Management Market is part of the Medical Devices Growth Partnership Service programme, which also includes research in the following markets: European Urinary Incontinence Devices Market, Issues; Trends and Prevalence in the European Cancer Therapy Market- Non Pharmaceutical and European Patient Temperature Management Systems. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available. GIL 2009: Europe Frost & Sullivan has expanded its flagship Global Congress on Corporate Growth - GIL Global - into several major cities around the world including London. For the first time ever in Europe, Frost & Sullivan will be hosting the Growth, Innovation and Leadership Congress "GIL 2009: Europe" on 19-20 May, at the Sofitel St James in London. GIL Global is the industry"s only event designed to support senior executives in their efforts to achieve sustainable, top-line growth. To register, obtain a programme agenda, explore sponsorship opportunities, or attend as a member of the media for GIL 2009: Europe, please contact Katja Feick, Corporate Communications Europe, at katja.feick@frost.com. One-on-One interviews with Frost & Sullivan senior growth consultants are also being scheduled. For more information you can also visit http://www.frost.com/gilglobal Frost & Sullivan


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009